formed to determine the efficacy of conventional surgery after therapy with SRS had proved inadequate.
Clinical Material and Methods

Patient Population
We retrospectively identified 88 patients (106 lesions) documented in our database who underwent resection of a metastatic brain lesion that previously had been treated with SRS at The University of Texas M. D. Anderson Cancer Center, hereafter referred to as M. D. Anderson, between June 1993 and August 2002. Clinical charts, operative notes, pathological reports, and neuroimages were reviewed. We defined our index case as consisting of a patient with at least one brain metastasis, but no more than three lesions at the time of surgery, who underwent conventional surgery after SRS had failed to alleviate the disease, but in whom conventional surgery had not been performed for that lesion prior to SRS. All lesions that fit the definition of the index case (index lesion) were included and reviewed independently. If a patient had one or two other lesions (in addition to the index lesion [s] ) that did not meet our definition, these were regarded as nonindex lesions. The focal treatment administered to all nonindex lesions and any other brain treatments that were used were recorded on time lines to allow their evaluation in relation to the treatment of the index lesion(s). Furthermore, if a patient had more than one index lesion, then we noted whether the patient underwent SRS or resection simultaneously or at separate times. The institutional review board at M. D. Anderson approved the conduct of this study and waived the requirement of informed consent.
Surgical Indications
The reason for surgical intervention was recorded as indicated by clinical observation, neuroimaging findings, or both. Clinical indications included intractable seizures (unresponsive to maximal medical therapy), a decreased level of consciousness, progressive motor weakness, gait ataxia, and aphasia. Neuroimaging indications included an enlarging lesion, hemorrhage, and mass effect from edema that was unresponsive to maximal medical therapy. In all cases, surgery was performed to achieve a gross-total resection of the lesion.
Postoperative Evaluation
All patients were assigned KPS 18, 19 scores approximately 30 days postoperatively, and these scores were compared with scores obtained at the time of the preoperative consultation. Patients were subgrouped according to the Radiation Therapy Oncology Group's RPA method (Table 1) . 13 Surgical specimens were submitted for histopathological assessment to determine whether there was a predominance of tumor or necrosis.
Surgical complications were defined as those occurring within 30 days after surgery. Complications were divided into three categories (neurological, regional, and systemic), with major and minor subclassifications that previously have been described. 26 Briefly, a complication was considered neurological if it directly produced a neurological deficit. Regional complications were those occurring within the cranium that were primarily related to the wound or the brain surface but did not directly result in a neurological deficit. Systemic complications were generalized medical conditions occurring at locations distant from the brain. Complications were regarded as major if they persisted for more than 30 days or required aggressive treatment because of their life-threatening nature. They were considered minor if they were not life threatening, did not prolong the hospital stay, and resolved within 30 days without surgical intervention. Operative mortality was defined as a death from any cause occurring within 30 days of the operation. The cause of death was deemed neurological if the systemic disease was stable, systemic if the neurological disease was stable, and combined if both systemic and neurological diseases were progressing.
To assess the response to resection after therapy with SRS had failed and to determine the local tumor recurrence rate, we compared postoperative magnetic resonance images obtained in each patient with all subsequent images. Local recurrence was defined as a tumor recurrence at the site of resection. If a new brain lesion occurred distant from the resection site, it was recorded as a distant recurrence. To assess dependency on steroid medications, we compared each patient's duration of continuous steroid use before and after resection.
Statistical Analysis
Survival curves measured from the time of surgery were estimated for each index case. Recurrences were computed based on Kaplan-Meier estimates. The Cox proportional hazards model 10 was used to identify the univariate and multivariate predictors of survival. Statistical analyses were performed using statistical software (SSPS version 10.1; SPSS Institute, Inc., Chicago, IL). Results were considered significant when probability values were less than or equal to 0.05.
Results
Patient Characteristics
Originally 88 patients were considered for this study. Twenty-seven patients were excluded: 22 patients because focal treatment (that is, conventional surgery) was conducted prior to SRS, which was followed by further resection, and five patients because they had four or more metastases. Sixty-one patients formed the final study group. The median age of the patients was 55 years (range 30-83 years). There were 37 men and 24 women. At the time of craniotomy, 28 patients (46%) had a single lesion, 24 (39%) had two lesions, and nine (15%) had three lesions, giving a total of 103 lesions. Seventy-four of these lesions satisfied the criteria for the index lesion, and the remaining 29 were regarded as nonindex lesions. Whole-brain radiation treatment was given to 36 patients (59%), either before or after resection. Preoperatively, 52 (85%) of the 61 patients had a KPS score of at least 70. Systemic disease at the time of surgery was stable in 37 patients (61%) and was progressing in 24 (39%). Systemic metastases were present in 42 patients (69%). Based on the Radiation Therapy Oncology Group's RPA criteria, 13% of the patients were in RPA Class I, 72% were in Class II, and 15% were in Class III. The specific indications for surgical intervention were based on both clinical and neuroimaging findings in 75% of the patients. In the remaining 25%, a lack of clinical improvement after SRS, either with (19%) or without (6%) changes on corresponding neuroimages, constituted the remaining indications. Clinical indications for surgery were present in 58 patients. These indications most frequently included weakness (31%) or seizures (26%) that were unresponsive to antiseizure medication and increased steroid dosage. The most common neuroimaging-related indications for surgery were increased tumor size (71%), worsening edema (13%), and hemorrhage (12%). Focal treatment, either surgery or SRS, for nonindex lesions was given to 29 (91%) of 32 patients. The median time interval from the SRS of an index lesion to craniotomy for its removal was 5.2 months (range 0.3-34.4 months).
Results of Craniotomy
In descending order the most common primary tumor histological types were melanoma (36%), lung adenocarcinoma (30%), renal cell carcinoma (16%), and breast adenocarcinoma (10%). Histological examinations of the 74 resected masses confirmed the predominance of tumor in 32 lesions (43%), necrosis in six lesions (8%), and equal proportions of tumor and necrosis in 36 lesions (49%).
After surgery performed for index lesions, the cancer recurred locally in four patients, distantly in 19 patients, and both locally and distantly in nine patients. The KaplanMeier estimate of the median time to any postoperative recurrence was 5 months (95% CI 3.6-6.4 months), that to a distant recurrence was 8.4 months (95% CI 6.6-10.3 months), and that to a local recurrence could not be estimated. The median pre-and postoperative KPS scores were both 80 and did not differ significantly (Wilcoxon rank test, p = 0.3).
Surgical complications (both major and minor) occurred in 12 patients (20%). Major surgical complications occurred in seven patients (12%). Most of these patients (five of seven) had major systemic complications. Specifically, three patients had venous thromboembolic disease that required placement of a blood clot filter in the inferior vena cava, and two patients had life-threatening pneumonia. Only one patient (2%) had a major neurological complication, permanent global aphasia, and only one patient had a major regional complication, a wound dehiscence secondary to infection that required surgical debridement. Minor surgical complications occurred in five patients (8%). In three of these patients (5%), the complications were neurological: two patients experienced episodes of transient speech difficulties and one patient displayed weak motor abilities that eventually returned to preoperative functional levels.
The duration of continuous steroid use, both before and after resection, was determined in 53 of 61 patients (Fig. 1) . In three patients steroid medications were not used, and in five patients we were unable to establish the duration of use. Conventional surgery facilitated the tapering off of steroid administration. In most patients, steroid use was tapered off within 2 to 4 weeks, with less than 5% of patients still receiving steroids at 12 weeks after resection. In contrast, 40% of patients were using steroids continuously for 12 weeks before conventional resection, which is consistent with dependency.
Patient Survival
Among the 61 patients in our study, 14 (23%) were alive at the last follow up with a median follow-up time of 19.1 months (range 5.5-46.8 months). The overall median survival time from the date of surgery for the 61 patients was 11.1 months (95% CI 6.8-15.4 months). Ten patients survived for more than 2 years after the craniotomy. The Kaplan-Meier estimate of the cumulative survival rate at 2 years was 25%. When the survival pattern was reviewed after subgrouping patients according to RPA classification (Fig. 2) , the overall median survival time of the eight RPA Class I patients could not be estimated, whereas the median survival time for the 44 RPA Class II patients was 11.1 months (95% CI 4.4-7.8 months) and that for the nine RPA Class III patients was 2.4 months (95% CI 1.8-3 months).
A univariate analysis (Table 2 ) was performed to determine which variables correlated with patient survival. In addition to the RPA classification, the status of the primary disease, the preoperative KPS score, the use of focal treatment for nonindex cases, and the major postoperative surgical complications were all significant univariate factors (p Ͻ 0.05). Patient age, the presence of other systemic metastases, the type of primary disease, the pathological findings (predominance of tumor or necrosis), the time interval from SRS to craniotomy, prior WBRT, and the number of brain lesions (one compared with two or three) did not significantly affect survival; however, these results could stem from the small sample size, which may have resulted in an insufficient statistical power to detect significance.
A multivariate analysis was performed to identify factors that could be used to ascertain which patients would benefit from this therapeutic approach. In the multivariate analysis, only preoperative RPA classification correlated signifi- cantly with survival time (Table 3) . One factor-aggressive focal treatment of all nonindex lesions-reached borderline significance; however, no other preoperative factors demonstrated statistical significance.
The cause of death was neurological in 15% of patients, systemic in 43%, both neurological and systemic in 34%, and undetermined in 8%. The surgical mortality rate was 3%, with two patients dying within 30 days after the surgical procedure. The causes of death in these two patients were systemic: one died of pneumonia and the other died of acute respiratory distress syndrome. Both patients had a preoperative KPS score of 70 but were older (69 and 82 years, respectively) than the median age for the whole group (55 years).
Discussion
To our knowledge, this study is the first to focus on outcomes of a series of patients with brain metastases who were treated with surgery after failure of SRS as the initial therapy. Our data demonstrate that following the failure of SRS to control brain metastases, resection can result in long-term control of these lesions and can positively influence overall patient survival. Specifically, the observed overall median survival time of 11.1 months is similar to that seen (11.5 months) in patients treated with repeated surgery for recurrence of a resected metastasis. 6 Furthermore, the survival time is also comparable to that reported for patients who have undergone an initial craniotomy for resection of brain metastases (range 9-15 months). 5, 7, 8, 28 In only one series have the results of repeated SRS for tumors not controlled by first-line SRS treatment been reported. 4 In that study the investigators analyzed both progressive primary and metastatic central nervous system tumors. Overall, patients in the benign tumor group had a longer median survival time than those in the malignant tumor group, most of whom had harbored primary malignant gliomas; less than 65% of patients with malignant tumors were alive at a median follow-up time of 10 months. 4 A direct comparison between our results and theirs is difficult because only four of the 26 patients included in that study had metastatic brain tumors.
Patients with recurrent brain metastases represent a formidable challenge to those involved in managing their care because many of these patients will have already received WBRT. Repeated radiation treatment has provided only limited palliative and survival benefits. 9 Furthermore, the potentially severe deleterious impact of WBRT on the patient's neurocognitive status has raised questions regarding its utility; 12 however, this remains a controversial issue within the neurooncology community. 22 Conversely, in a previous study, we demonstrated that repeated operation for previously resected brain metastases had a positive impact on patient outcome. 6 The overall lesion recurrence rate after a second surgical procedure (when the first treatment was surgery) was 54%. In the present study, in which surgery followed the failure of local tumor control by SRS, the overall recurrence rate was 52%. Although these overall recurrence rates were similar (Table 4) , the local recurrence rate was lower when surgery was performed after local control failure of SRS-21%-than it was in the repeated operation group, in which the local recurrence was 48% (p = 0.003). The reason for this is unclear; SRS may be able to control microsatellite metastases. Conversely, the recurrence rate of distant tumor was much lower in the repeated operation group (17%) than in the group in which surgery was performed after SRS failed to provide local control (46%) (p = 0.001). This difference may have been a result of a selection bias in the surgical series in which patients with advanced or progressive disease were excluded from repeated craniotomy.
The data on complications, morbidity, and mortality in this series are comparable to those seen after resection of recurrent brain metastases that have been previously treated with surgery. 6 In the present study, the major neurological complication rate was only 2%, which is actually less than the rate reported for patients who initially undergo craniotomy for resection of a brain metastasis (~ 6%). 5, 23, 25 Two patients were considered to have died of surgical complications, but the cause was systemic and not neurological in both cases. This leads us to conclude that the resection of brain metastases that have failed to be controlled by firstline SRS can be accomplished without an increased risk of neurological morbidity. In addition to the low neurological complication rate, we also found that steroid dependency was less of an issue in patients after resection. In contrast, 40% of the patients received steroid medications for 12 consecutive weeks before surgery despite having received SRS. Clearly, these patients had some degree of steroid dependency.
We explored factors associated with a good prognosis. The type of primary tumor, whose distribution is affected by the patterns of patient referral to the institution, had no impact on the overall survival of the patients in our series. Furthermore, a histopathological finding of more tumor material than necrosis in the resected lesion(s) did not adversely affect the patient's overall survival. This was an unexpected finding because the presence of tumor tissue should, intuitively, correlate with a poorer prognosis.
As is evident from the results of the univariate and multi-
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Surgery after previous radiosurgery 213 variate analyses, the single most important factor influencing duration of survival was a patient's RPA classification. Clearly, patients in RPA Class I or II did significantly better than patients in RPA Class III. The validity of the RPA classification for stratifying patients with brain metastases into survival groups is well known. 14 Nevertheless, the utility of the RPA classification scheme may not be universal across all patient subgroups, particularly given the myriad complex treatments and recurrence sequences that may be encountered clinically. In a recent report investigators have questioned the usefulness of the RPA classification scheme in patients with more than four metastases. 20 Nevertheless, our results support the use of the RPA classification scheme as a prognostic indicator for patients undergoing resection of metastatic brain lesions that SRS has failed to control.
The only other factor that may be a significant preoperative indicator, based on our findings, is the extent of focal treatment of nonindex lesions. This factor was statistically significant in the univariate analysis (Table 2 ) and nearly significant in the multivariate analysis (Table 3 ). The finding that nonindex lesions should be treated aggressively is consistent with findings in previous studies. 7, 24 In our previous study of the role of surgery for multiple brain metastases, the survival rate of patients with multiple metastases was similar to that of patients with single metastases as long as all lesions were removed. Thus, we were not surprised to find that patients who had undergone aggressive treatment (surgery or SRS) for nonindex lesions fared better than patients who underwent only nonfocal treatment (chemotherapy or WBRT) or no treatment.
Finally, our finding that metastases that had not been controlled by an initial treatment with SRS could be removed by performing conventional surgery with only a 2% rate of major neurological complications raises an important issue regarding the treatment of patients with brain metastases. In the absence of a randomized trial that shows SRS to be superior to conventional surgery in the initial treatment of small (Ͻ 1.5 cm maximum diameter) brain metastases, both are viable options as first-line therapy. 1, 3, 23, 28 Although the low complication rate we observed for performing conventional surgery after the failure of local tumor control by SRS might lead some to suggest that all small brain metastases should be initially treated with SRS and that conventional surgery should be reserved for local control failures, we do not wish to advocate this or to imply that surgery is not the definitive treatment in many cases. Empirical use of SRS would also be inappropriate in patients harboring an unknown primary tumor or a lesion whose appearance was ambiguous on neuroimages, in whom a tissue diagnosis becomes paramount to determine the appropriate adjuvant therapy; in patients in whom the lesion is too large and SRS is almost guaranteed to fail; 8 or in patients with a better chance for long-term survival in whom the use of conventional surgery as the initial therapy would be more appropriate.
Conclusions
This is the first published description of patient outcomes when surgery is used to treat brain metastases previously treated by SRS. Our results document that selected patients who undergo resection of brain metastases that were not controlled by initial treatment with SRS can have a good outcome and are less likely to become dependent on steroid medications. The rates of both local tumor recurrence and median overall survival indicate that surgery can provide long-term control of the treated lesions. Furthermore, patients with a favorable RPA classification (Class I or II) and patients whose nonindex lesions are aggressively treated with focal modalities are most likely to benefit from resection in this specific scenario. 
